Abstract:

Aims: Dapagliflozin, a sodium-glucose cotransporter-2 inhibitor, is indicated for glycemic control in type 2 diabetes mellitus (T2DM). In this study, we investigated the changes in neutrophil-to-lymphocyte ratio (NLR), a marker of inflammation, in patients with T2DM after the initiation of dapagliflozin. Methods: This retrospective study included patients (aged 18 to 75 years) with T2DM who were prescribed dapagliflozin 10 mg once daily additional to their existing diabetic treatment. Patients with a history of chronic liver disease, chronic renal failure, infection, inflammatory disease, and the use of drugs affecting bone marrow were included. The duration of treatment was set at 12 weeks. Results: The study included 98 patients with a mean age of 54.3±8.0 years, with a female predominance of 61.2%. At 12th week, there was a statistically significant decrease in fasting glucose ​​(199.6 mg/dL vs. 164.3 mg/dL, p<0.001), glycated hemoglobin (HbA1c) ​​(8.92% vs. 8.01%, p<0.001), leukocyte count (7.79 103/mm3 vs. 8.36 103/mm3, p=0.018) and neutrophil count (4.44 103/mm3 vs. 4.84 103/mm3, p=0.027). Lymphocyte count (2.56 103/mm3 vs. 2.72 103/mm3, p=0.150) and NLR (1.86 vs. 1.89, p=0.758) also showed some increase but the difference was not statistically significant. Conclusions: This study showed significant increases in leukocyte and neutrophil counts in T2DM patients taking dapagliflozin, but lymphocyte count and NLR remained unaltered.

Keywords: